CSIMarket
 


Igc Pharma Inc   (IGC)
Other Ticker:  
 

Igc Pharma Inc 's Quick Ratio

IGC's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Regardless of the sequential decrease in Current Liabilities, during the third quarter 2023, Quick Ratio deteriorated to 0.71 below Igc Pharma Inc 's average Quick Ratio.

Within Major Pharmaceutical Preparations industry 45 other companies have achieved higher Quick Ratio than Igc Pharma Inc in third quarter 2023. While Quick Ratio total ranking has improved so far during the III Quarter 2023 to 530, from total ranking in the second quarter 2023 at 1362.

Explain Quick Ratio?
How much Cash & cash equivalents IGC´s has?
What are IGC´s Current Liabilities?


IGC Quick Ratio (Dec 31 2023)
III. Quarter
(Sep 30 2023)
II. Quarter
(Jun 30 2023)
I. Quarter
(Mar 31 2023)
IV. Quarter
(Dec 31 2022)
III. Quarter
Y / Y Current Liabilities Change 42.77 % 52.39 % 28.45 % -22.24 % 6.02 %
Y / Y Cash & cash equivalent Change -72.62 % -54.17 % -75.79 % -67.97 % -57.85 %
Quick Ratio MRQ 0.71 1.48 0.92 1.77 3.71
IGC's Total Ranking # 530 # 1362 # 1317 # 1367 # 866
Seq. Current Liabilities Change -8.07 % -1.17 % 12.28 % 39.97 % -1.88 %
Seq. Cash & cash equivalent Change -55.89 % 60.21 % -41.79 % -33.44 % -26.16 %



Quick Ratio third quarter 2023 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 46
Healthcare Sector # 96
Overall Market # 530


Quick Ratio Statistics
High Average Low
50.9 4.2 0.13
(Dec 31 2018)  




Financial Statements
Igc Pharma Inc 's Current Liabilities $ 2 Millions Visit IGC's Balance sheet
Igc Pharma Inc 's Cash & cash equivalent $ 1 Millions Visit IGC's Balance sheet
Source of IGC's Sales Visit IGC's Sales by Geography


Cumulative Igc Pharma Inc 's Quick Ratio

IGC's Quick Ratio for the trailling 12 Months

IGC Quick Ratio

(Dec 31 2023)
III. Quarter
(Sep 30 2023)
II. Quarter
(Jun 30 2023)
I. Quarter
(Mar 31 2023)
IV. Quarter
(Dec 31 2022)
III. Quarter
Y / Y Current Liabilities TTM Growth 42.77 % 52.39 % 28.45 % -22.24 % 6.02 %
Y / Y Cash & cash equivalent TTM Growth -72.62 % -54.17 % -75.79 % -67.97 % -57.85 %
Quick Ratio TTM 1.21 1.8 2.53 3.69 4.44
Total Ranking TTM # 1617 # 3635 # 1514 # 3566 # 66
Seq. Current Liabilities TTM Growth -8.07 % -1.17 % 12.28 % 39.97 % -1.88 %
Seq. Cash & cash equivalent TTM Growth -55.89 % 60.21 % -41.79 % -33.44 % -26.16 %


On the trailing twelve months basis Due to decrease in Current Liabilities in the III Quarter 2023 to $1.94 millions, cumulative Quick Ratio decreased to 1.21 below the Igc Pharma Inc average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 122 other companies have achieved higher Quick Ratio than Igc Pharma Inc . While Quick Ratio overall ranking has improved so far to 1617, from total ranking during the twelve months ending second quarter 2023 at 3635.

Explain Quick Ratio?
How much Cash & cash equivalents IGC´s has?
What are IGC´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 123
Healthcare Sector # 293
Within the Market # 1617


trailing twelve months Quick Ratio Statistics
High Average Low
22.73 3.89 0.3
(Sep 30 2019)   (March 31, 2014)




Companies with similar Quick Ratio in the quarter ending Dec 31 2023, within Major Pharmaceutical Preparations Industry Quick RatioDec 31 2023 MRQ Cash & cash equivalentDec 31 2023 MRQ Current Liabilities
Ampio Pharmaceuticals inc   1.95 $ 4.089  Millions$ 2.102  Millions
Nextcure Inc   1.90 $ 13.082  Millions$ 6.883  Millions
Immunic Inc   1.89 $ 46.674  Millions$ 24.729  Millions
Catalyst Pharmaceuticals Inc   1.81 $ 137.636  Millions$ 76.063  Millions
Macrogenics Inc   1.80 $ 100.956  Millions$ 56.108  Millions
Beigene ltd   1.76 $ 3,183.273  Millions$ 1,810.113  Millions
Endo International Plc  1.76 $ 945.621  Millions$ 538.794  Millions
Eterna Therapeutics Inc   1.74 $ 7.575  Millions$ 4.357  Millions
Vaxxinity Inc   1.73 $ 30.395  Millions$ 17.605  Millions
Amicus Therapeutics inc   1.71 $ 286.200  Millions$ 167.689  Millions
23andme Holding Co  1.68 $ 242.418  Millions$ 144.139  Millions
Eyenovia inc   1.56 $ 14.851  Millions$ 9.530  Millions
Kiora Pharmaceuticals Inc  1.55 $ 2.455  Millions$ 1.587  Millions
Ani Pharmaceuticals Inc  1.52 $ 221.121  Millions$ 145.477  Millions
Avenue Therapeutics Inc   1.49 $ 1.783  Millions$ 1.196  Millions
Ptc Therapeutics inc   1.45 $ 876.739  Millions$ 603.100  Millions
Biovie Inc   1.45 $ 20.227  Millions$ 13.981  Millions
Procyon Corporation  1.44 $ 0.839  Millions$ 0.583  Millions
Ainos Inc   1.41 $ 1.886  Millions$ 1.337  Millions
Clene Inc   1.38 $ 35.000  Millions$ 25.330  Millions
Eton Pharmaceuticals Inc   1.32 $ 21.388  Millions$ 16.241  Millions
Evolus Inc   1.30 $ 62.838  Millions$ 48.291  Millions
2seventy Bio Inc   1.25 $ 74.958  Millions$ 59.779  Millions
Sonnet Biotherapeutics Holdings Inc   1.14 $ 3.021  Millions$ 2.654  Millions
Cartesian Therapeutics Inc   1.13 $ 76.911  Millions$ 68.209  Millions
Kamada Ltd   1.12 $ 55.641  Millions$ 49.593  Millions
Azitra Inc   1.12 $ 1.796  Millions$ 1.603  Millions
Nature s Sunshine Products inc   1.07 $ 82.373  Millions$ 76.753  Millions
Inflarx N v   0.98 $ 18.547  Millions$ 18.866  Millions
Jazz Pharmaceuticals Plc  0.98 $ 1,506.310  Millions$ 1,536.692  Millions

Date modified: 2024-02-16T23:20:05+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com